Can Septrin Double Strength Be Given With Linezolid?
Yes, Septrin (co-trimoxazole) double strength can be combined with linezolid, and this combination is specifically used to provide broad-spectrum coverage for MRSA plus additional gram-negative and atypical organisms in serious infections.
What This Combination Covers
This dual-antibiotic regimen targets:
- MRSA (Methicillin-Resistant Staphylococcus aureus) - covered by linezolid
- Additional gram-positive organisms - covered by both agents
- Gram-negative bacteria - covered by co-trimoxazole (linezolid has NO gram-negative activity)
- Pneumocystis jirovecii - covered by co-trimoxazole
- Other organisms: Nocardia, Listeria, Stenotrophomonas, Toxoplasma - covered by co-trimoxazole
Clinical Scenarios Where This Combination Is Used
1. MRSA Bone and Joint Infections
The IDSA MRSA guidelines explicitly recommend TMP-SMX (co-trimoxazole) 3.5-4.0 mg/kg/dose every 8-12 hours as an option for osteomyelitis and septic arthritis 1. When combined with linezolid, you achieve:
- Enhanced MRSA coverage
- Broader spectrum for polymicrobial bone infections
- Oral step-down option for prolonged therapy
2. MRSA Central Nervous System Infections
For meningitis, brain abscess, or epidural abscess, the guidelines list TMP-SMX 5 mg/kg/dose every 8-12 hours as an alternative agent 1. Combining with linezolid (which has excellent CNS penetration) provides:
- Dual MRSA coverage
- Linezolid's superior CSF penetration
- Co-trimoxazole's additional spectrum
3. Polymicrobial Diabetic Foot Infections
The diabetic foot infection guidelines note that narrow-spectrum agents like linezolid should be combined with other agents (e.g., a fluoroquinolone) if polymicrobial infection is suspected 2. Co-trimoxazole serves this role by adding gram-negative coverage that linezolid completely lacks.
4. Severe Skin and Soft Tissue Infections
For necrotizing fasciitis or complicated SSTIs requiring MRSA coverage plus broader spectrum, combining linezolid with co-trimoxazole addresses:
- MRSA and other gram-positives (linezolid)
- Potential gram-negative co-pathogens (co-trimoxazole)
- This is particularly relevant when cultures are pending 3
Critical Safety Considerations
Serotonin Syndrome Risk - MAJOR CONCERN
Both linezolid and co-trimoxazole have weak MAOI properties. The FDA label warns about serotonin syndrome when linezolid is combined with serotonergic agents 4. While co-trimoxazole is not typically listed as a major serotonergic drug, monitor closely for:
- Confusion, agitation, restlessness
- Tremors, muscle rigidity
- Hyperthermia, diaphoresis
- Autonomic instability
Avoid other serotonergic medications (SSRIs, SNRIs, TCAs, MAOIs) when using this combination.
Myelosuppression - Monitor Weekly
Linezolid causes dose-dependent bone marrow suppression 4. Co-trimoxazole also causes myelosuppression. When combined:
- Obtain baseline CBC
- Monitor CBC weekly (mandatory for linezolid >2 weeks)
- Watch for anemia, thrombocytopenia, leukopenia
- Consider discontinuation if worsening cytopenias develop
Duration Limitations
- Linezolid should generally be limited to ≤28 days due to toxicity risk
- For longer courses, consider transitioning to co-trimoxazole monotherapy if appropriate based on cultures
Gram-Negative Coverage Gap
Critical pitfall: Linezolid has ZERO gram-negative activity 4. The FDA label explicitly states: "Linezolid has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected" 4.
This is why co-trimoxazole is valuable in this combination - it fills the gram-negative gap.
Dosing Recommendations
Linezolid: 600 mg PO/IV every 12 hours 1
Co-trimoxazole (Septrin DS):
- For bone/joint infections: 3.5-4.0 mg/kg/dose (based on TMP component) every 8-12 hours 1
- For CNS infections: 5 mg/kg/dose every 8-12 hours 1
- For an 80-kg adult: 2 DS tablets (each DS = 160 mg TMP) achieves approximately 4 mg/kg 1
When NOT to Use This Combination
- Confirmed gram-positive-only infection - linezolid alone is sufficient
- Renal insufficiency - both drugs require dose adjustment; co-trimoxazole is contraindicated in severe renal failure
- Baseline cytopenias - additive myelosuppression risk
- Patients on serotonergic medications - increased serotonin syndrome risk
- Sulfa allergy - absolute contraindication to co-trimoxazole
Alternative Combinations
If you need MRSA coverage plus gram-negative activity but want to avoid this combination:
- Linezolid + fluoroquinolone (levofloxacin or moxifloxacin) 2
- Vancomycin + co-trimoxazole
- Daptomycin + co-trimoxazole (not for pneumonia - daptomycin inactivated by surfactant)